CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding

P J Adam; J A Terrett; G Steers; L Stockwin; J A Loader; G C Fletcher; L-S Lu; B I Leach; S Mason; A C Stamps; R S Boyd; F Pezzella; K C Gatter; A L Harris

doi:10.1038/sj.bjc.6603222

Figure 2

An external file that holds a picture, illustration, etc.
Object name is 95-6603222f2.jpg

CD70 protein is expressed at the cell-surface of kidney cancer-derived cell lines. An anti-CD70 mAb was used in the context of FACS analysis to determine relative cell-surface protein levels for A498, 786-0, SW839 and ACHN renal carcinoma cell lines. The immortalised embryonic kidney line HEK293 was included as a ‘normal’ kidney cell line control. In addition, as CD70 expression was first described in B/T cells, a panel of cell lines with this derivation was included. The CD19+ or CD3+ subsets of PBMCs were also analysed to confirm the previously observed absence of binding to these cells. Results demonstrated that expression of CD70 was highest in A498 and 786-0 cells. Immunocytochemical analysis was subsequently used to support the finding that CD70 antibody binds to the surface of A498 cells (inset).